Natera, Inc. (NASDAQ:NTRA - Get Free Report)'s share price fell 2.8% during mid-day trading on Friday . The company traded as low as $159.67 and last traded at $163.86. 214,963 shares were traded during mid-day trading, a decline of 81% from the average session volume of 1,147,069 shares. The stock had previously closed at $168.50.
Several equities research analysts have issued reports on the company. Guggenheim increased their target price on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday. The Goldman Sachs Group increased their target price on shares of Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, October 16th. Craig Hallum raised their price target on Natera from $121.00 to $157.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. TD Cowen upped their price target on shares of Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Finally, Robert W. Baird boosted their price target on Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and an average price target of $160.63.
Check Out Our Latest Stock Report on NTRA
The company's 50 day moving average price is $163.51 and its two-hundred day moving average price is $133.77. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $21.51 billion, a P/E ratio of -92.53 and a beta of 1.65.
Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million for the quarter, compared to analysts' expectations of $361.43 million. During the same quarter last year, the business earned ($0.95) EPS. The firm's revenue was up 63.9% compared to the same quarter last year. Equities analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current year.
In other Natera news, CEO Steven Leonard Chapman sold 1,709 shares of the company's stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84. Following the transaction, the chief executive officer now owns 194,615 shares in the company, valued at approximately $23,501,707.40. This represents a 0.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 256 shares of Natera stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total value of $30,737.92. Following the sale, the insider now directly owns 111,891 shares of the company's stock, valued at $13,434,752.37. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 123,409 shares of company stock valued at $20,045,631 in the last 90 days. Insiders own 7.60% of the company's stock.
Large investors have recently modified their holdings of the company. Envestnet Asset Management Inc. lifted its position in Natera by 1.2% during the second quarter. Envestnet Asset Management Inc. now owns 187,438 shares of the medical research company's stock worth $20,298,000 after buying an additional 2,148 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Natera by 35.6% in the second quarter. Dimensional Fund Advisors LP now owns 264,801 shares of the medical research company's stock valued at $28,680,000 after acquiring an additional 69,523 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Natera by 8.2% during the second quarter. Renaissance Technologies LLC now owns 216,500 shares of the medical research company's stock worth $23,445,000 after purchasing an additional 16,317 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in Natera in the second quarter valued at $2,359,000. Finally, Virtu Financial LLC lifted its stake in Natera by 20.1% during the second quarter. Virtu Financial LLC now owns 9,288 shares of the medical research company's stock worth $1,006,000 after purchasing an additional 1,552 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.